PDCD1 and neoplasm: As the most widely applied companion biomarker for PD-1 blockade therapy in NSCLC, detection of PD-L1 on tumor cells is of limited clinical value due to its unsatisfactory predictive power, varying thresholds, as well as spatial and temporal variations (Mansfield et al. 2016; Ilie et al. 2016).